Metraipolis › archive › dc_18895cc13efa

Emerging Precision Therapeutic Strategies in Pancreatic Ductal Adenocarcinoma: KRAS Targeting, DDR Vulnerabilities, Immune Redirection, and Tumor… — Europe PMC PMID:42654051

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42654051
DOI
10.3390/pharmaceutics18080934
License (as archived)
solo-consultazione
Archived
2026-10-17T09:48:53.526Z
SHA-256 of the archived text
396723bb70d3f2b23c32aa8334a5425f376599f26238bf1b9b79f1f38b67ae5e
Stable URL of this page
https://metraipolis.com/documento/dc_18895cc13efa

How to cite

Emerging Precision Therapeutic Strategies in Pancreatic Ductal Adenocarcinoma: KRAS Targeting, DDR Vulnerabilities, Immune Redirection, and Tumor… — Europe PMC PMID:42654051 — Europe PMC (en), https://europepmc.org/article/MED/42654051 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_18895cc13efa (Metraipolis archive dc_18895cc13efa, sha256 396723bb70d3f2b23c32aa8334a5425f376599f26238bf1b9b79f1f38b67ae5e)
BibTeX
@misc{dc18895cc13efa,
  title = {Emerging Precision Therapeutic Strategies in Pancreatic Ductal Adenocarcinoma: KRAS Targeting, DDR Vulnerabilities, Immune Redirection, and Tumor… — Europe PMC PMID:42654051},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42654051},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_18895cc13efa; sha256 396723bb70d3f2b23c32aa8334a5425f376599f26238bf1b9b79f1f38b67ae5e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42654051. Agents can read the archived copy with the MCP tool read_document.